Status:
COMPLETED
HORMA: Hormonal Regulators of Muscle and Metabolism in Aging
Lead Sponsor:
National Institute on Aging (NIA)
Conditions:
Sarcopenia
Muscle Weakness
Eligibility:
MALE
65-90 years
Phase:
PHASE2
Brief Summary
The purpose of this study is to determine the relationship of deficiencies in testosterone and growth hormone to loss of muscle mass (sarcopenia) and functional impairment during aging and whether the...
Detailed Description
Elderly persons experience progressive loss of skeletal muscle mass, muscle strength, and functional capacity for activities of daily living. Aging is also associated with a loss of hormones believed ...
Eligibility Criteria
Inclusion
- Men who are 65-90 years of age
- Total serum IGF-1 (insulin-like growth factor) in the lower tertile for adults (56-167 ug/dl)
- Total serum testosterone of 150-550 ng/dL
Exclusion
- BMI (Body Mass Index) 35 kg/m2 or greater
- Weight instability (\>3% change in prior 3 months)
- Daily intake of total kilocalories less than or equal to 0.8X the RDA and intake of protein between 0.8 and 1.4 g/kg/day inclusive
- Acute illness in the prior 30 days
- Resistance training (wt lifting) in the past 12 months
- Vigorous aerobic sports (Competing as a Master athlete in the prior 5 years; weekly swimming, racquet ball, cycling, tennis, in preceding 12 months)
- Use of an anabolic agent (androgen, androgen precursor, rhGH, etc) in the preceding 12 months
- Use of medications that might affect amino acid metabolism (e.g. beta-adrenergic blockers, beta-agonists, Ca2+ channel blockers, corticosteroids)
- Fasting sugar greater than or equal to 126 mg/dl or diabetes requiring Rx
- History of benign intracranial hypertension
- Heart failure, active angina, or myocardial infarction in the prior 6 months or history of aortic stenosis
- Uncontrolled hypothyroidism or hyperthyroidism
- Rheumatoid arthritis, cirrhosis or active hepatitis
- History of carpal tunnel syndrome
- Prior cancer other than squamous or basal cell carcinoma of the skin
- Sleep apnea or severe chronic lung disease
- Anticoagulation with heparin or coumadin
- Blood pressure not controlled with medication to \<180/95 mm Hg
- Calculated creatinine clearance \<50 cc/min
- Serum prostatic antigen \>4.0 or American Urological Association score greater than or equal to 8
- Hematocrit greater than or equal 52%, or ALT \>1.5X ULN
- Failure to pass a modified Bruce treadmill stress test
- Severe disability limiting strength or physical function testing
- Dementia or cognitive impairment affecting a subject's ability to provide informed consent
Key Trial Info
Start Date :
September 1 2002
Trial Type :
INTERVENTIONAL
Allocation :
ESTIMATED
End Date :
February 1 2007
Estimated Enrollment :
108 Patients enrolled
Trial Details
Trial ID
NCT00183040
Start Date
September 1 2002
End Date
February 1 2007
Last Update
June 2 2009
Active Locations (2)
Enter a location and click search to find clinical trials sorted by distance.
1
Tufts University
Boston, Massachusetts, United States, 02111
2
Washington University School of Medicine
St Louis, Missouri, United States, 63108